Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Contingent consideration by Quarter
Contingent consideration — Remaining potential development & regulatory milestones (historical, $M) ($M)
Vertex Pharmaceuticals Contingent consideration: $678M in Q4 2023, unchanged from a year earlier. That is the highest of the 17 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
Source: Form 10-K (filed 2024-02-15) ↗
Reported in Form 10-Q / 10-K Fair Value Measurements Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contingent consideration — Remaining potential development & regulatory milestones (historical, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 678 | 0.0% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2023 | Sep 30, 2023 | 678 | 0.0% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 678 | 0.0% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 678 | 0.0% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 678 | 0.0% | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2022 | Sep 30, 2022 | 678 | 0.0% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2022 | Jun 30, 2022 | 678 | 0.0% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 678 | 0.0% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 678 | 0.0% | Form 10-K (filed 2022-02-09) ↗ |
| Q3 2021 | Sep 30, 2021 | 678 | 0.0% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 678 | 0.0% | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2021 | Mar 31, 2021 | 678 | 0.0% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 678 | 0.0% | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2020 | Sep 30, 2020 | 678 | – | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2020 | Jun 30, 2020 | 678 | – | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | 678 | – | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 678 | – | Form 10-Q (filed 2026-08-04) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Contingent consideration ($M), quarterly Q4 2019–Q4 2023 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/cc-rem-milestone
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.